L.J.Davis, PharmD (@MedicineDigest) header
L.J.Davis, PharmD (@MedicineDigest) profile picture

Professor of Practice, Clinical and Regulatory Affairs

San Francisco, CA
Joined August 2009
Photo by L.J.Davis, PharmD (@MedicineDigest)Photo by L.J.Davis, PharmD (@MedicineDigest)Photo by L.J.Davis, PharmD (@MedicineDigest)Photo by L.J.Davis, PharmD (@MedicineDigest)Photo by L.J.Davis, PharmD (@MedicineDigest)Photo by L.J.Davis, PharmD (@MedicineDigest)Photo by L.J.Davis, PharmD (@MedicineDigest)Photo by L.J.Davis, PharmD (@MedicineDigest)Photo by L.J.Davis, PharmD (@MedicineDigest)Photo by L.J.Davis, PharmD (@MedicineDigest)
FDA’s shift to daily FAERS adverse event data releases has been a step forward for transparency, but better signal management, and clearer direction for public interpretation is needed to truly enhance the value of postmarket safety surveillance. www-nejm-org.ccl.idm.oclc.or…
13
FDA grants accelerated approval to drugs intended for serious or life-threatening conditions giving earlier patient access using surrogate markers as primary endpoints. Of 52 such oncology drugs, 69% had postmarket safety actions at a median of 2.2 years. jamanetwork.com/journals/jam…
15
Potential inappropriate prescribing cascades (PIPCs; a drug to tx anothers side effects) are common in older adults,increase tx burden,reduce adherence,& heighten hospitalization risk. This BMJ paper lists 24 PIPCs that could inform prescribing practices. pubmed.ncbi.nlm.nih.gov/4272…
15
L.J.Davis, PharmD retweeted
Longevity product marketing is out of control, but there are established FDA pathways for the evidence required to get approvals. A @ScienceMagazine policy forum "Rather than leaning into deregulation, dedicating resources to validating endpoints and to enforcing existing regulation is what will best serve the public, advance science, and promote innovation." science.org/doi/10.1126/scie…
12
33
3
111
25,493
L.J.Davis, PharmD retweeted
There hasn't previously been a treatment vs pancreatic cancer this successful. Striking improved (a > doubling) survival results @NEJM and @ASCO today with daraxonrasib, which also became available via an FDA approved early access program and began shipping to physicians this week @RevMedicines nejm.org/doi/full/10.1056/NE…
29
418
51
1,733
206,136
L.J.Davis, PharmD retweeted
📉25% LOWER ALL-CAUSE MORTALITY! Wowzers—one of the largest long-term safety studies ever undertaken—offers the clearest answer yet: “Among 28 million French adults aged 18–59, those who received an mRNA-based COVID-19 vaccine were less likely to die in the subsequent four years than those who remained unvaccinated, corresponding to a 25% lower risk of death from all causes.”—and works even better among young adults—⬇️35% lower risk for ages 18-29! Links in thread 🧵 below👇
156
1,184
134
3,357
628,476
Chronic traumatic encephalopathy (CTE): A degenerative brain disorder in some people who have had repeated head impacts over time.
1
43
Lancet meta analysis from 68 studies. Effectiveness Findings: Primary Series Vax (Against Any SARS-CoV-2 Strain) - Against hospitalizations: 92% at baseline, waning to 79% by 224–251 days. Against mortality: 91% at baseline, waning to 86% by 168–195 days. thelancet.com/journals/lanre…
Based on what I experienced as a paramedic. They gave the Covid shots to destroy a portion of the population and remove people from our military that were smart enough to refuse. This was an attack. It still is an ongoing attack. And those alive that push for the covid shot, are mentally unstable. God bless
41
Lancet meta analysis from 68 studies. Effectiveness Findings: Primary Series Vax (Against Any SARS-CoV-2 Strain) - Against hospitalizations: 92% at baseline, waning to 79% by 224–251 days. Against mortality: 91% at baseline, waning to 86% by 168–195 days. thelancet.com/journals/lanre…
No they don’t. That’s why we broke free from you.
50
Interesting scientific and ethical discussion on heathspan extension defined as the “period of life spent in good health, free from the chronic diseases and disabilities of aging” vs lifespan extension. I think the answer is both...
33
Though FDA has started to crack down on deceptive drug advertising once again, violative drug promotion from industry paid social media influencers (SMIs) is more difficult to monitor though SMIs are required by the FTC to clearly state sponsor support. bmj.com/content/391/bmj.r250…
37
Clinical Trials using AI with human in the loop - AI for hypotheses generation, humans conducting the clinical trial.
AI and the new Science of Medicine "the science of medicine is ready for reinvention" "AI generates hypotheses, but those hypotheses are tested the old-fashioned way, avoiding the myriad statistical problems of relying on AI alone for discovery." nejm.org/doi/full/10.1056/NE… @NEJM by @oziadias
24
A potential neural mechanism via the small guanosine triphosphatase Ras-related protein 1 (Rap1) has been identified for metformin action.
Metformin, the first line drug for Type 2 diabetes, has been used for 60 years without a clearcut mechanism of action. It turns out it's not just reducing glucose output from the liver. Metformin also works via the brain science.org/doi/10.1126/scia…
1
46
Patient/subjects are truly the heroes of clinical research...
Data from the second human treated with a prime edited medicine: a 56-year-old male with chronic granulotamous disease (CGD) had his bone marrow prime edited to insert the missing GT in NCF1, restoring NADPH oxidase function in neutrophils (DHR positivity) several fold beyond the therapeutic threshold. His intestinal inflammation is now normal, and his prime-edited HSCs rapidly engrafted with 15 days post-transplant, consistent with well-tolerated editing. Each new therapeutic technology is dependent on brave patients willing to be among the first humans to receive a new type of treatment. For prime editing, that's this patient, and an 18-year old who also responded in a similarly encouraging manner. Patient #2 sent our lab a kind message, noting that helping other patients with rare diseases was deeply meaningful to him. Data from @PrimeMedicine.
34
🚨Using Real-World Evidence (RWE) in drug development faces hurdles like data quality, standardization & analysis validity. Ensuring RWE meets FDA standards is key to advancing safety & efficacy decisions. FDA Guidance. #Pharma #Regulations fda.gov/regulatory-informati…
38
🚨 Aging & Biotech: Regulatory hurdles for anti-aging drugs are steep—aging isn't FDA-classified as a disease, and biomarkers for efficacy remain elusive. Ethical issues & high trial costs add complexity. #Longevity #Biotech womblebonddickinson.com/us/i…
25
And this... well, what about patent monopolies, other countries paying less, old drugs not going generic, executive compensation, direct to consumer advertising, and other concerns? For more on why those issues are not the problem, or are solvable: nopatientleftbehind.org.
Replying to @PeterKolchinsky
And if upon hearing that the drug industry saves lives (shout out @davidfrum) you think "but what about?!", no worries. I've got you covered. There's a link at end to a "But what about?!" article. Here: rapport.bio/supplementals/bu…
34
Everyone calls Pharma/Biotech the bad guys. Crunching the numbers tells a different story. Pharma accounts for only 8% of the healthcare spend, improves our lives and drives down costs. Excellent post by @PeterKolchinsky with Thanksgiving talking points!
Healthcare costs are high, but there's an 8% slice that does more than anything else to improve our lives & drive down costs. (& if drug prices come up during TG dinner, here are talking points) Credit to @Steven_Ballmer for sparking this. rapport.bio/all-stories/best… @NPLB_org
36
FDA issues multiple warning letters targeting online sales of unapproved Mounjaro, Ozempic. Despite statements their products are “research chemicals only” their websites established that the products are intended to be drugs for human use. fda.gov/inspections-complian…
27